Our analysis of other publicly available ovarian cancer data sets [35–38] revealed that ATAD2 mRNA expression was higher in metastatic and high-grade ovarian cancer samples (Fig. 1E-G) and was associated with increased incidence of recurrence in patients (Fig. 1H). Here, ATAD2 is linked to ovarian cancer.